SH3GL1

Across TCGA pan-cancer cohorts, SH3GL1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SH3GL1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SH3GL1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SH3GL1 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where SH3GL1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SH3GL1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.668	<.001	12	view →
HNSC	Male	IV	−0.288	<.001	8	view →
LSCC	Male	II,III,IV	+0.161	<.001	8	view →
PDAC	Female	All	+0.295	<.001	4	view →
LUAD	Female	III,IV	−0.232	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SH3GL1–CCRCC

Open the CCRCC breakdown →